CID-103 (SC)

About CASI Pharmaceuticals

CASI Pharmaceuticals' mission is to address urgent unmet medical needs in organ transplant rejection and autoimmune diseases through its lead candidate, CID-103. The company has established a commercial footprint in China with products like EVOMELA® and FOLOTYN®, generating revenue to support its R&D. Its strategy hinges on advancing CID-103 as a first-in-class therapy for AMR while leveraging its China commercial platform for sustainable growth. Key achievements include building a dual-region management team and advancing CID-103's preclinical and clinical development.

Therapeutic Areas